Literature DB >> 1739534

Myocardial dysfunction in treated adult hypopituitarism: a possible explanation for increased cardiovascular mortality.

M Shahi1, S A Beshyah, D Hackett, P S Sharp, D G Johnston, R A Foale.   

Abstract

OBJECTIVE: To assess cardiac structure and function in patients with treated hypopituitarism and to determine their relation to the degree of growth hormone deficiency and body composition pattern.
DESIGN: 26 patients with treated hypopituitarism were studied by cross sectional and Doppler echocardiography and by exercise testing. The results were analysed and their relation to the degree of growth hormone deficiency and body composition determined.
SETTING: All tests were performed in the department of cardiology and the unit of metabolic medicine at a tertiary referral centre. PATIENTS: Patients with hypopituitarism referred for endocrine assessment. MAIN OUTCOME MEASURES: Left ventricular mass, left ventricular diastolic function, and exercise capacity in patients with hypopituitarism and their relation to growth hormone deficiency.
RESULTS: Mean (SD) serum concentration of insulin-like growth factor 1 (IGE-1), a measure of growth hormone deficiency, was 82.4 (45) micrograms/l. Lean body mass calculated by measuring total body potassium was 50 (9) kg. All patients had a normal left ventricular mass index and a normal left ventricular ejection fraction. Eight patients had abnormal left ventricular diastolic function. There was a significant correlation between IGF-1 and left ventricular mass (r = 0.45, p less than 0.02). Lean body mass was also significantly correlated with left ventricular mass (r = 0.78, p less than 0.0001) and left ventricular diastolic function (r = -0.63, p less than 0.01). The mean exercise duration was 8.6 (3.6) minutes. There was a significant correlation between serum IGF-1 and the rate-pressure product on exercise (r = 0.47, p less than 0.01). Seven patients had planar ST segment depression greater than 0.1 mV during exercise testing. In five of these patients there was rapid resolution of ST segment depression immediately after exercise. Two patients developed considerable ST segment depression, and subsequent coronary angiography showed normal coronary arteries. Exercise-induced ST segment depression was not related to the severity or duration of growth hormone deficiency or serum cholesterol concentration.
CONCLUSIONS: This study suggests that left ventricular mass and the rate-pressure product are related to the degree of growth hormone deficiency, that left ventricular diastolic dysfunction is frequently seen in hypopituitarism, and that these patients may have ischaemic-like ST segment changes during exercise testing. These findings may explain the increased cardiovascular mortality in patients with hypopituitarism and may also have implications for growth hormone replacement therapy in adults.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1739534      PMCID: PMC1024710          DOI: 10.1136/hrt.67.1.92

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  19 in total

1.  EXERCISING TESTING IN ADULT NORMAL SUBJECTS AND CARDIAC PATIENTS.

Authors:  R A BRUCE; J R BLACKMON; J W JONES; G STRAIT
Journal:  Pediatrics       Date:  1963-10       Impact factor: 7.124

Review 2.  The measurement of insulin-like growth factor I: clinical applications and significance.

Authors:  J D Teale; V Marks
Journal:  Ann Clin Biochem       Date:  1986-07       Impact factor: 2.057

3.  Cardiac failure responding to growth hormone.

Authors:  R C Cuneo; P Wilmshurst; C Lowy; G McGauley; P H Sönksen
Journal:  Lancet       Date:  1989-04-15       Impact factor: 79.321

4.  Influence of aging on Doppler echocardiographic indices of left ventricular diastolic function.

Authors:  P Spirito; B J Maron
Journal:  Br Heart J       Date:  1988-06

5.  The relation of total body potassium to height, weight, and age in normal adults.

Authors:  K Boddy; P C King; R Hume; E Weyers
Journal:  J Clin Pathol       Date:  1972-06       Impact factor: 3.411

6.  Beneficial effects of growth hormone treatment in GH-deficient adults.

Authors:  J O Jørgensen; S A Pedersen; L Thuesen; J Jørgensen; T Ingemann-Hansen; N E Skakkebaek; J S Christiansen
Journal:  Lancet       Date:  1989-06-03       Impact factor: 79.321

7.  Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden.

Authors:  L Lapidus; C Bengtsson; B Larsson; K Pennert; E Rybo; L Sjöström
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-10

8.  Standardization of M-mode echocardiographic left ventricular anatomic measurements.

Authors:  R B Devereux; E M Lutas; P N Casale; P Kligfield; R R Eisenberg; I W Hammond; D H Miller; G Reis; M H Alderman; J H Laragh
Journal:  J Am Coll Cardiol       Date:  1984-12       Impact factor: 24.094

9.  Increased myocardial contractility following growth hormone administration in normal man. An echocardiographic study.

Authors:  L Thuesen; J S Christiansen; K E Sørensen; J O Jørgensen; H Orskov; P Henningsen
Journal:  Dan Med Bull       Date:  1988-04

10.  The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency.

Authors:  F Salomon; R C Cuneo; R Hesp; P H Sönksen
Journal:  N Engl J Med       Date:  1989-12-28       Impact factor: 91.245

View more
  15 in total

1.  The potential for growth hormone in the management of heart failure.

Authors:  J P Monson; G M Besser
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

2.  Growth hormone status predicts left ventricular mass in patients after cure of acromegaly.

Authors:  Tamara L Wexler; Ronen Durst; David McCarty; Michael H Picard; Lindsay Gunnell; Zehra Omer; Pouneh Fazeli; Karen K Miller; Anne Klibanski
Journal:  Growth Horm IGF Res       Date:  2010-07-03       Impact factor: 2.372

Review 3.  Medical management of hypopituitarism in patients with pituitary adenomas.

Authors:  Baha M Arafah
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

4.  Early-onset growth hormone deficiency results in diastolic dysfunction in adult-life and is prevented by growth hormone supplementation.

Authors:  L Groban; M Lin; K A Kassik; R L Ingram; W E Sonntag
Journal:  Growth Horm IGF Res       Date:  2011-03-02       Impact factor: 2.372

5.  Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans.

Authors:  G Bisi; V Podio; M R Valetto; F Broglio; G Bertuccio; G Del Rio; E Arvat; M F Boghen; R Deghenghi; G Muccioli; H Ong; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-04       Impact factor: 4.256

6.  The GH/IGF-1 Axis and Heart Failure.

Authors:  Graziella Castellano; Flora Affuso; Pasquale Di Conza; Serafino Fazio
Journal:  Curr Cardiol Rev       Date:  2009-08

7.  Structural, functional and autonomic changes in the cardiovascular system in growth hormone deficient patients.

Authors:  Doğan Erdoğan; Tufan Tükek; Ferihan Aral; Hüseyin Oflaz; Mehmet Ozaydin; Orhan Kocaman; Vakur Akkaya; Taner Gören; Senay Molvalilar
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-01       Impact factor: 1.468

8.  Left ventricular diastolic function abnormalities in hypopituitary patients with GH deficiency: evidence for a subclinical cardiomyopathy.

Authors:  N Ozbey; A Sezgil; H Oflaz; B Umman; Y Orhan; E Sencer; S Molvalilar
Journal:  J Endocrinol Invest       Date:  2002 Jul-Aug       Impact factor: 4.256

9.  Three weekly injections (TWI) of low-dose growth hormone (GH) restore low normal circulating IGF-I concentrations and reverse cardiac abnormalities associated with adult onset GH deficiency (GHD).

Authors:  A I Pincelli; R Bragato; M Scacchi; G Branzi; G Osculati; R Viarengo; G Leonetti; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

Review 10.  Cardiovascular effects of growth hormone.

Authors:  W J Brickman; B L Silverman
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.